2Q Revenues: $10.4 billion (+26%)
2Q Loss: $739 million (earnings were $741 million 2Q19)
YTD Revenues: $14.7 billion (+52%)
YTD Earnings: $2.3 billion (-29%)
Comments: Revenues from the Immunology portfolio were $5.3 billion, up 8%. U.S. Humira sales were nearly $4 billion, up 5%; International Humira sales were $863 million, down 20% due to biosimilar competition. Skyrizi sales were $330 million. Rinvoq revenues were $149 million. Revenues from the Hematologic Oncology portfolio were $1.6 billion, up 26%. Global Imbruvica sales were $1.3 billion, up 17%, with U.S. revenues of $1.1 billion and international profit sharing of $233 million. Global Venclexta sales were $303 million. Revenues from the Aesthetics portfolio were $481 million with Global Botox Cosmetic sales of $226 million. Results reflect acquisition related costs related to the transaction, financing and integration costs of the Allergan acquisition.